Immune drugs useful for psoriasis
Key points
- New research shows that tacrolimus ointment and pimecrolimus cream, which suppress the immune system, are effective treatments for intertriginous psoriasis, a form of the scaly skin disease affecting body regions where skin rubs against skin.
- These findings stem from two studies reported in the Journal of the American Academy of Dermatology.
- Hartle, from Fujisawa Healthcare, Inc. in Beaver Falls, Pennsylvania, and colleagues assessed the outcomes of 167 psoriasis patients treated with tacrolimus ointment or inactive cream twice daily.
- After little more than a week of treatment, tacrolimus therapy was associated with significantly higher response rates.
New research shows that tacrolimus ointment and pimecrolimus cream, which suppress the immune system, are effective treatments for intertriginous psoriasis, a form of the scaly skin disease affecting body regions where skin rubs against skin.
These findings stem from two studies reported in the Journal of the American Academy of Dermatology.
In the first study, Dr. Jennifer E. Hartle, from Fujisawa Healthcare, Inc. in Beaver Falls, Pennsylvania, and colleagues assessed the outcomes of 167 psoriasis patients treated with tacrolimus ointment or inactive cream twice daily.
After little more than a week of treatment, tacrolimus therapy was associated with significantly higher response rates. Nearly 25 percent of tacrolimus-treated patients experienced clearing or marked improvement of their lesions compared with just 5.8 percent of comparison subjects.
After 8 weeks of treatment, the complete or near-complete response rate in the tacrolimus group was 65.2 percent, while the rate in the comparison group was 31.5 percent.
Lastly, the side effects seen with tacrolimus were comparable to those observed with the inactive cream, the authors note.
In the second study, Dr. Anne Parneix-Spake, from Novartis Pharmaceuticals Corp in East Hanover, New Jersey, and colleagues evaluated the outcomes of 57 patients with intertriginous psoriasis who were treated with pimecrolimus or inactive cream twice daily.
As in the first study, a clear difference in response rates between the two treatments emerged early on. By week 2, complete or near-complete resolution was noted in 54 percent of pimecrolimus-treated patients compared with just 21 percent of comparison subjects.
At 8 weeks, 82 percent of patients in the pimecrolimus group reported complete or good control of their disease compared with just 41 percent of comparison subjects, the authors note. Once again, side effects were comparable in each group.
"Pimecrolimus cream 1% represents a new and attractive therapeutic option for the treatment of (intertriginous) psoriasis," they conclude.
SOURCE: Journal of the American Academy of Dermatology, November 2004.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Skin, Hair & Beauty →
NewsSecond Course of Alefacept Often Successful for Plaque Psoriasis Even if First Course Fails
Chronic plaque psoriasis patients who do not improve on their initial treatment with the targeted agent alefacept appear to respond well to a second course of treatment, according to research presented February 19th at…
22 February 2005
NewsExtended Raptiva therapy safe, effective for psoriasis
Treatment with the relatively new drug Raptiva for 12 weeks has been shown to be a safe and effective treatment for moderate-to-severe chronic psoriasis. Now, new research indicates that the benefits are even more…
20 January 2005
NewsPlaque Psoriasis
This is the most common type of psoriasis. It typically appears as thick, flaky patches of skin on one or more parts of the body. Sometimes the patches of affected skin are large, extending over much of the body. The…
